Opinion

» opinion and brain

Most Recent

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

0 Comments

image: Opinion: Pay-to-Play Publishing

Opinion: Pay-to-Play Publishing

By | September 3, 2015

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

2 Comments

image: Opinion: Can the Brain Be Trained?

Opinion: Can the Brain Be Trained?

By | March 23, 2015

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

5 Comments

image: Opinion: Sexual Dysfunction Matters

Opinion: Sexual Dysfunction Matters

By | August 19, 2013

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

7 Comments

image: Opinion: On Living Longer

Opinion: On Living Longer

By | June 24, 2013

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

2 Comments

image: Opinion: Toxicants and the Brain

Opinion: Toxicants and the Brain

By | June 17, 2013

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

1 Comment

image: Opinion: The Present and Future of Neurogenomics

Opinion: The Present and Future of Neurogenomics

By | June 13, 2013

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

0 Comments

image: Opinion: BRAIN Is Not Enough

Opinion: BRAIN Is Not Enough

By | June 6, 2013

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

4 Comments

image: Opinion: Super Storm Sandy

Opinion: Super Storm Sandy

By | October 31, 2012

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

12 Comments

image: Opinion: Fishy Deaths

Opinion: Fishy Deaths

By | October 29, 2012

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

1 Comment

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech